A quiet revolution is underway in global healthcare - one that’s transforming how we treat diabetes, obesity, and perhaps even addiction. It doesn’t come from a new diet fad or fitness trend, but from a simple weekly injection. I will explain here in detail, how this revolution will create a new Gold Rush for the Indian Pharmaceutical Industry going forward.

The new class of drugs called GLP-1 (Glucagon – like – peptide) agonists, led by Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro have become nothing short of a phenomenon. They not only regulate blood sugar but also trigger meaningful weight loss, often up to 15 - 20 percent of body weight. In a world battling obesity and metabolic disorders, this isn’t just medicine, it’s a megatrend.

The Science Behind the Breakthrough:

See Full Page